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Abstract
This paper provides an educational review covering the consideration of costs for cost-efectiveness analysis (CEA), summaris-
ing relevant methods and research from the published literature. Cost data are typically generated by applying appropriate unit 
costs to healthcare resource-use data for patients. Trial-based evaluations and decision analytic modelling represent the two main 
vehicles for CEA. The costs to consider will depend on the perspective taken, with conlicting recommendations ranging from 
focusing solely on healthcare to the broader ‘societal’ perspective. Alternative sources of resource-use are available, including 
medical records and forms completed by researchers or patients. Diferent methods are available for the statistical analysis of 
cost data, although consideration needs to be given to the appropriate methods, given cost data are typically non-normal with 
a mass point at zero and a long right-hand tail. The choice of covariates for inclusion in econometric models also needs careful 
consideration, focusing on those that are inluential and that will improve balance and precision. Where data are missing, it is 
important to consider the type of missingness and then apply appropriate analytical methods, such as imputation. Uncertainty 
around costs should also be relected to allow for consideration on the impacts of the CEA results on decision uncertainty. Costs 
should be discounted to account for diferential timing, and are typically inlated to a common cost year. The choice of methods 
and sources of information used when accounting for cost information within CEA will have an efect on the subsequent cost-
efectiveness results and how information is presented to decision makers. It is important that the most appropriate methods are 
used as overlooking the complicated nature of cost data could lead to inaccurate information being given to decision makers.
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Key Points for Decision Makers 
Not appropriately controlling for the nature of cost data 
and the uncertainty around subsequent cost estimates 
used in cost-efectiveness analysis (CEA) could lead to 
inaccurate information being given to decision makers.
Although checklists exist for use alongside CEA to aid 
transparency in the methods used, there is still poor 
reporting and rationalisation of statistical methods and 
covariate adjustments when using cost data.
It is diicult to suggest a ‘one size its all’ methodol-
ogy when estimating and analysing cost data for CEA; 
therefore, it is down to the researcher to assess the nature 
of the cost data to determine which methods to use.
1 Introduction
Economic evaluation is widely used for the appraisal of 
healthcare programmes, taking into account both the costs 
and the efects or outcomes. There are multiple forms of 
economic evaluation, such as cost-beneit analysis (CBA), 
cost-efectiveness analysis (CEA) and, as a subform of 
CEA, cost-utility analysis (CUA). However, all forms 
of economic evaluation are related to ‘value for money’, 
with ‘costs’ representing an integral aspect of the evalua-
tion process owing to the resultant opportunity costs from 
resources not being available for other purposes [1]. In the 
UK, CEA, particularly CUA as the National Institute for 
Health and Care Excellence (NICE) economic evaluation 
reference case [2], has become the most common form of 
economic evaluation. This is also relected within reim-
bursement agency guidance internationally [3]. Therefore, 
this paper focuses speciically on CEA, although many of 
the aspects described and discussed are relevant to other 
forms of economic evaluation, such as CBA.
A large amount of research has already been dedicated 
to how we measure and statistically estimate outcomes 
for CEA, with particular focus often on utility data and 
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the quality-adjusted life-year (QALY) associated with 
CUA [4]; in 2017, PharmacoEconomics published a spe-
cial issue titled ‘Estimating Utility Values for Economic 
Evaluation’ on this exact subject [5]. Guidance on how 
we do the same for costs has become dated, do not relect 
advances in CEA more generally, new methods are not 
presented in a user friendly manner in a single source 
(i.e. methods are often spread across multiple and various 
papers and publications) and there is not always consensus 
on the ‘best’ method to use. As a result, some useful and 
new methods have not been widely adopted.
This educational review summarises relevant methods 
and research from the published literature about how to 
identify, estimate and analyse relevant cost data based on 
two speciic vehicles for economic evaluation (within-trial 
and modelling-based analyses), within which we focussed 
on the following nine topics: (1) the diference between 
resource use and costs; (2) vehicles for CEA (e.g. within-
trial and modelling-based analysis); (3) what costs to 
include depending on the costing perspective; (4) sources 
of resource-use data and unit costs; (5) statistical methods 
for assessing cost data and its distribution; (6) adjusting 
for baseline covariates; (7) dealing with diferent types of 
missing cost data; (8) uncertainty around cost estimates; 
and (9) a note on discounting, inlation and using relevant 
currency. We also identify gaps in the literature based on 
what the authors perceive are important and overlooked 
considerations when analysing cost data, and therefore 
suggest future areas for research. This educational review 
provides a range of references for further reading, and 
should therefore be used as a reference guide to get an 
understanding about using cost data for CEA, rather than 
a technical document describing in detail speciic meth-
odologies associated with using cost data.
2  Resource Use and Costs: What 
is the Diference?
The focus of this paper is cost data, which can be obtained 
by applying unit costs to resource-use data; therefore, we 
need to clarify what are (1) resource-use data; (2) unit costs; 
and (3) cost data.
Resource-use data represent those resources consumed by 
the person or population with the health condition of inter-
est for the CEA. For example, common types of healthcare 
resource-use information include number and type of visits 
to hospital (e.g. inpatient, outpatient, critical care) and any 
medications prescribed (e.g. type of drug, dose and duration 
of treatment).
Resource-use information can be analysed in its own right 
(e.g. as the response variable in regression analysis or as a 
descriptive statistic), although due to its close relationship 
with costs, and costs being one of the key aspects for CEA, 
it is cost data that is normally the focus of CEA. To generate 
cost data from resource use, we need to apply appropriate 
unit costs to each type of resource use. Unit costs are the cost 
per unit of item of resource use (e.g. there is a diferent unit 
cost for seeing a doctor compared with seeing a nurse) and 
represent the monetary value of that item (e.g. if a consulta-
tion with a doctor has a unit cost of £31, this represents the 
monetary cost of a consultation). Sources of resource-use 
data and unit costs are described in more detail in Sect. 5.
3  Vehicles for Cost‑Efectiveness Analysis 
(CEA): Within‑Trial and Modelling‑Based 
Analysis
Evidence-based healthcare generally relies on the use of 
clinical studies to provide the necessary clinical and eco-
nomic information. Randomised controlled trials (RCTs) are 
regarded as the ‘gold standard’ type of clinical study [6]. An 
economic evaluation that uses mainly information from the 
trial and estimates costs and efects over the trial period isre-
ferred to as a ‘within-trial economic evaluation’ [7]; this is in 
contrast to synthesising evidence from multiple sources (e.g. 
RCTs, empirical literature, and expert opinion) to estimate 
costs and efects in ‘modelling-based analyses’ [8].
The focus on RCTs as a ‘gold standard’ has given a per-
ceived level of ‘reliability’ to the evidence they produce, 
including the associated within-trial CEA; however, they 
have their limitations. Economic evaluation to inform efec-
tive decision making requires that costs and efects can be 
estimated for all relevant comparators over an appropri-
ate time horizon [9]. Furthermore, all available evidence 
and potential sources of heterogeneity in cost efectiveness 
should be considered [10]. RCTs typically consider only a 
few of the relevant comparators over a short time horizon, 
often in a particular group of patients with limited exter-
nal validity of trial results. As a result of these limitations, 
decision analytic modelling methods are now widely used, 
although the two vehicles can be complementary such that 
a decision model can be used to expand on those aspects not 
addressed as part of the within-trial analysis (e.g. evaluating 
over a longer time horizon). Models provide a framework for 
synthesising evidence, comparing all relevant comparators 
and estimating costs and efects over an appropriate time 
horizon [11]. A limitation of modelling is that they can be 
considered a ‘black box’ where the inputs and outputs (and 
everything in between) may not be transparent to decision 
makers interested in the CEA. Furthermore, models, by 
necessity, represent simpliied versions of reality and may 
not be considered to accurately relect real life. However, 
these limitations can be partially avoided by being transpar-
ent with all methods and sources of information used when 
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conducting a CEA and following prespeciied checklists 
during the evaluation and write-up process, e.g. the Con-
solidated Health Economic Evaluation Reporting Standards 
(CHEERS) statement [12], which provides guidance on how 
to report economic evaluations more consistently and with 
transparency, and the Philips et al. [13] checklist based on a 
review of guidelines for good practice in decision-analytic 
modelling for health technology assessment (HTA). Other 
authors have also suggested pragmatic steps to improve the 
validation of models [14].
Many diferent types of decision analytic model have 
been used for economic evaluation [8, 11, 13, 15], including 
simple decision trees, state-transition models (e.g. Markov 
models) [16], individual sampling models (e.g. discrete 
event simulations [17]), and more complex structures (e.g. 
dynamic transmission models [18]). Despite diferences, the 
approaches all aim to relect the possible prognoses of indi-
viduals being modelled through the initial interventions they 
receive, the time they spend in particular health states, and 
the clinical events they experience, all of which are associ-
ated with speciied costs. For example, if the initial interven-
tion was a drug treatment, the cost would typically involve 
deining the dose (which may be conditional on patient char-
acteristics such as weight or body surface area), treatment 
duration (which may be conditional on survival from the 
model), and the associated unit cost.
Costs can be applied to speciic health states, whereby a 
health state can represent, for example, a declined state of 
health (e.g. New York Heart Association Functional Classi-
ication states [19]), or be deined by the healthcare received 
(e.g. outpatient, inpatient, or moving to a care home). Costs 
associated with being in a health state would usually be cal-
culated by estimating the average costs over a deined time 
period in that state (e.g. in a Markov model, a cycle length), 
and then the total health state costs are estimated conditional 
on the time spent in that health state over the deined time 
period. Most commonly, the resources associated with being 
in that health state (e.g. the average number of primary and 
secondary care appointments associated with a year with sta-
ble angina) are estimated and then unit costs are applied to 
these to estimate the total cost over the deined time period 
[20]. Methods for the estimation of resource use (described in 
more detail in Sect. 5) vary from the analysis of resource-use 
data from patients to the use of clinical opinion [20]. The costs 
of an event are typically applied as a one-of cost in models 
and relect the resource use and costs associated with treat-
ing an event (e.g. the cost of treating a myocardial infarction). 
The resources associated with the treatment of an event are 
estimated and the unit costs applied to estimate the total cost 
of an event.
With the costing of health states and events, there is also the 
possibility of using longitudinal data and panel data analysis to 
estimate the background costs of being in a health state (using 
dummy variables for patients in particular health states in a 
given period) and the costs of events (again using a dummy 
in the cycle in which the event occurred) [21]. There is also 
a growing interest in how observational and real-world data, 
such as that from ‘Big Data’ (a term often used nowadays to 
refer to extremely large data sets that include a much higher 
number of data points, parameters, and/or people than what 
was historically available for analysis), can be used for the 
purpose of economic analysis rather than relying on trials. 
Big Data can also be used to conduct either a (observational) 
within-study analysis or inform an economic model, the statis-
tical considerations for which are diferent to when conducting 
an analysis alongside a trial or a model. As this is a grow-
ing area, observational studies as a vehicle for CEA are not 
extensively described within this manuscript, but form part 
of a discussion point in Sect. 11. A framework for conduct-
ing economic evaluations alongside natural experiments (i.e. 
“naturally occurring circumstances in which subsets of a popu-
lation have diferent level of exposure to a supposed causal 
factor, in a situation resembling an actual experiment where 
human subjects would be randomly allocated to groups” [22]), 
the resource-use data requirements for which will typically rely 
on the existence of longitudinal ‘Big Data’, has been described 
by Deidda et al. [23].
4  What Costs to Include: A Brief Introduction 
to Costing Perspectives
Cost-effectiveness analysis seeks to provide analysis to 
inform decision making, and crucial to which costs should 
be included or excluded is the decision makers themselves, 
their priorities, and their budgets [11]. Thinking about the 
choice of relevant costs also presents issues of pragmatism; 
for example, costs common to all mutually exclusive inter-
ventions may not be relevant to the decision being informed, 
since these costs will not impact on incremental costs. 
From a healthcare or payer perspective, it is important to 
include costs beyond the initial direct cost (e.g. the acquisi-
tion cost of a new pharmaceutical product) and to include 
other healthcare costs within the time horizon adopted for 
the analysis. There is a debate about whether to include 
all future healthcare costs or just those in related disease 
areas [24, 25], with conlicting recommendations from the 
US Panel stating all healthcare costs being included [26], 
and NICE stating that only related future costs should be 
included [2]. The US Panel also advocates the use of a ‘soci-
etal’ perspective, which entails incorporating additional 
costs into CEA beyond those in the healthcare sector; for 
example, costs of informal care and lost productivity [26]. 
The way in which costs from diferent sectors can be aggre-
gated for use in this perspective is also debated in emerg-
ing literature [27, 28]. Finally, irrespective of perspective, 
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there are questions relating to which types of costs should 
be incorporated within economic evaluations; for example, 
if sunk and ixed costs should be included. This may be par-
ticularly relevant to evaluations involving large investments, 
in which case the question becomes what approach should be 
taken: (1) a ‘short-run’ approach whereby factors of produc-
tion are ixed, such as capital (e.g. large medical scanners 
such as magnetic resonance imaging (MRI) machines); or 
(2) a long-run approach whereby factors of production are 
not ixed. A useful discussion of these issues can be found 
in the articles by Drummond et al. [11] and Culyer [29].
5  Sources of Resource‑Use Data and Unit 
Costs: Examples from England
In order to assess costs for CEA, there is a need for acces-
sible and good-quality data that relect the care people 
receive. Alongside trials, Ridyard and Hughes [30] identi-
ied the following ive data collection methods.
1. Medical records (e.g. patient notes, large databases).
2. Prospective forms completed by trial researchers or 
healthcare professionals:
2.1. not based on patient recall or abstracted from rou-
tine sources, or
2.2. based on patient recall.
3. Patient-completed or carer-/non-healthcare professional-
completed:
3.1. diaries, or
3.2. forms.
The majority of studies (61/85) identiied by Ridyard and 
Hughes [30] used at least two methods, typically involving 
patient- or carer-completed forms and medical records (the 
latter referred to here as ‘routinely collected care data’); for 
the purpose of discussion, it is these two methods in Eng-
land that are the focus. Regarding data sources in non-UK 
settings, a brief discussion of conducting economic evalua-
tions alongside multinational trials (which includes obtain-
ing resource-use and unit cost information) is provided in 
Sect. 10 for consideration by the interested reader.
Instruments for person-reported cost measurement have 
been developed, with the Client Service Receipt Inventory 
(CSRI) the most commonly used example [31], however 
it has been adapted/modiied many times (estimated to be 
over 200) and is therefore neither fully standardised nor uni-
versally applicable [32]. Standardising instruments may be 
considered useful for cross-study comparisons, allowing for 
easier comparison across CEAs, which could be perceived 
as similar to the debate around using generic outcome meas-
ures for CEA [33, 34] and the EQ-5D as the NICE reference 
case [2, 35]; the counter to which could also be perceived as 
similar to those rationalisations for using condition-speciic 
measures for outcome measurement [36]—that there are 
speciic aspects of resource use and costs that are important 
in certain, but not all, decision problems. As such, standard-
ised resource-use measurement instruments may not be spe-
ciic enough to capture all important resources for particular 
decision problems. There are other examples of established 
resource-use instruments [37–39]—those in development 
[40], and the Database of Instruments for Resource-Use 
Measurement (DIRUM), which was created as a repository 
for instruments based on patient recall (http://www.dirum 
.org) [41]. Researchers tend to tailor instruments to focus on 
speciic information needed for analysis, which is particu-
larly important when taking a broader perspective, such as 
information related to informal care and other wider aspects 
that are not routinely collected within medical records or in 
large databases.
The method of using routinely collected data can include 
anything from raw data extracted straight from a service, to 
the level of linked datasets across multiple services. Exam-
ples of using raw data extracted from multiple care services 
(i.e. primary, secondary, and social care services) for the 
purpose of a costing study include the study by Franklin 
et al. [42] and two subsequent RCT-based CEAs [43, 44]. 
Within England, National Health Service (NHS) Digital is 
one major provider of routinely collected data. The most 
widely used NHS Digital dataset is Hospital Episode Sta-
tistics (HES) [45]. For primary care, McDonnell et al. [46] 
have amalgamated a list of UK datasets that may be of inter-
est (not all contain resource-use information). An issue with 
electronic datasets is that they may only adequately record 
data for that particular service; thus, previous studies have 
described the need for linked data [47–49]. Asaria et al. [50] 
have described key challenges and opportunities of using 
linked records to estimate healthcare costs. There are also 
concerns with data quality and missingness within such large 
datasets that require assessment and validation [51, 52], and 
the exchangeability of using person-reported or routine care 
data is also questionable as they may produce quite diferent 
estimates [53, 54]. With the advent of routinely collected 
data, there is a growing interest in how to utilise these data 
in trials, observational studies, and modelling, the methodol-
ogy for which will develop as these data become more acces-
sible and reliable [48, 55]. It is important to note that no 
data collection method can currently be considered the ‘gold 
standard’. The trade-of between self-reported and routinely 
collected electronic data to inform the choice of method for 
trial-based evaluations has been described by Franklin and 
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Thorn [55]. The same type of discussion relevant to develop-
ing economic models is currently lacking.
There are some common unit cost sources in the UK, 
including NHS Reference Costs [56], Personal Social Ser-
vices Research Unit (PSSRU) Unit Costs of Health and 
Social Care [57], British National Formulary (BNF; for 
drug costs) [58], and the drugs and pharmaceutical elec-
tronic market information tool (eMIT, for generic drugs) 
[59], among others. NHS reference costs are strongly asso-
ciated with HES data, particularly in relation to inpatient, 
outpatient and accident and emergency (A&E) visits. Geue 
et al. [60] have discussed the implications of using (ive) 
alternative methods for costing hospital episode statistics, 
and recommend using a Health Resource Grouper (HRG) 
costing method that can be directly linked with NHS Refer-
ence Costs; we also recommend using this method.
6  Statistical Methods for Assessing Cost 
Data and Its Distribution
As Briggs and Gray [20] point out, within CEA, the parame-
ter of interest is usually the mean cost (or diference between 
group means) or, less frequently, mean resource use. This is 
because such research is typically aimed at estimating the 
expected costs (and associated cost efectiveness) of alterna-
tive comparators, relecting that costs will difer across indi-
viduals but it is the mean cost that is important. Cost data 
are typically non-normal in their distribution, with a mass 
point at zero, non-negative, and with a long right-hand tail, 
with the implicit underlying data-generating process result-
ing in heteroskedastic errors, and non-linear responses to 
covariates [61]. According to central limit theorem [62], in 
large samples, estimated mean cost parameters are approxi-
mately normally distributed despite the non-normality of the 
underlying data, which would mean that standard methods 
based on ordinary least squares (OLS) and the t distribution 
could be appropriate for characterising the uncertainty in 
the estimate of the mean. However, with inite samples it is 
not clear when the sample size is ‘large enough’ to use these 
standard methods, especially when data are skewed [20].
Regression methods are used to analyse observable het-
erogeneity and control for chance imbalance between trial 
arms to provide an unbiased estimate of the mean cost or 
incremental cost [63]. Important issues around how to 
choose covariates are discussed in Sect. 7. In this section, we 
focus on issues concerning the choice of regression method. 
A number of alternative approaches have been developed 
for addressing questions regarding cost data using statistical 
and econometric methods. A useful review of these meth-
ods, particularly for application to datasets from trials, has 
been conducted by Mihaylova et al. [64]. A comprehensive 
evaluation of many of these methods using UK observational 
data, conducted by Jones et al. [65], found that no single 
method is dominant and that trade-ofs between bias (perfor-
mance of predictions on average) and accuracy (performance 
of individual predictions) exist. For researchers perform-
ing regression analysis on resource use, diferent regression 
methods may be more appropriate, e.g. methods for count 
data such as negative binomial regression [66]. Depending 
on the nature of the response variable, other approaches may 
be warranted, but often the same methods used for costs are 
transferable [61].
Cost data often possess a large number of zero costs, 
although there are examples where cost data are not likely 
to have zero costs (e.g. advanced-stage cancer patients [67, 
68]). Literature is available on how best to deal with the 
presence of a large number of zero costs, which includes 
the use of a two-part model where separate regressions ana-
lyse the chance of non-zero observations and the value of a 
non-zero observation [66]. It is not favoured to use selection 
models in this context, although they can and have been 
used, because zero costs are not the result of censoring but 
are instead generally considered to be genuine zeros [69].
In the context of economic evaluation, transforming data 
either via logarithmic transformation or some other function 
is not favoured [70]. The principle reason for this is that the 
arithmetic mean cost is the parameter of interest and that 
retransforming costs to the natural scale requires diicult 
calculations, particularly when there is heteroskedasticity 
[70]. In addition, when applying a logarithmic transforma-
tion, an adjustment to zero costs or estimation of a two-part 
model are required. Instead, researchers typically employ 
generalised linear models (GLMs), which can be applied to 
data with a mass point at zero and which allow researchers to 
model costs directly on the scale of interest using a linear or 
non-linear speciication for how covariates afect the mean 
and variance, with the latter allowing for forms of heter-
oskedasticity [71]. GLMs comprise a link function, which 
determines the relationship between a linear index of covari-
ates and the mean, and a distribution function, which deter-
mines the relationship between the mean and the variance 
[70]. While researchers tend to adopt a log-link function 
with a Gamma distribution function, there is no evidence 
that this is the dominant form of GLM in terms of model 
it for cost data applications, and numerous tests and plots 
are available to inform model selection [72]. In addition, 
a more lexible speciication of a GLM, the extended esti-
mating equations (EEE) model, can estimate the best-itting 
function choices from the data [73]. Despite the lexibility of 
GLMs available through the choice of link and distribution 
functions, interested readers may wish to read more around 
some of the implicit distributional assumptions in GLMs 
[74, 75] and issues with applying GLMs to heavy-tailed data 
[76].Owing to the diiculties in choosing the most appro-
priate distribution for cost data, researchers may decide to 
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employ a non-parametric approach to analysis as opposed to 
a parametric or semi-parametric method. Bootstrapping is 
one such approach that can be applied to regression, which, 
instead of making distributional assumptions, makes use of 
the original data to produce an empirical estimate of the 
sampling distribution of the statistic in question [20]. Briggs 
and Gray [20] discuss the validity of this approach, applying 
the method and contrasting with a transformation approach 
in ive examples. Other methods include model averaging 
and those based on Bayesian approaches [64].
Cost data in economic evaluation may have additional 
characteristics that afect the choice of regression method. 
In particular, in the context of cluster trials, clustering in the 
data will exist. The appropriate methods for analysing such 
data include multilevel models, generalised estimating equa-
tions (GEE) and two-stage, non-parametric bootstrap [77]. It 
is worth noting that these approaches can be considered as 
extensions of OLS, GLMs and bootstrapping. Cost data may 
also be censored, which is discussed as a special form of 
missing data in Sect. 8. Finally, cost data are often analysed 
to inform model parameters, such as the cost of a health state 
or event, which are likely to be observed at diferent points in 
time across patients. Examples of this kind of analysis can be 
found in the study by Walker et al. [21], and typically require 
methods for analysing longitudinal data, such as panel ixed 
efects or GEE (of which panel random efects is one form). 
Note that analysis of this kind, where analysis is based on 
an event or health state, assumes causality can be inferred, 
which may not be the case. If this is not the case, meth-
ods for handling unobserved confounding may be required 
if there is insuicient observable information available to 
determine causality; an overview of approaches in economic 
evaluation is presented by Faria et al. [78]. Interested readers 
may also wish to consider methods that can handle unob-
served confounding, along with distributional considerations 
for cost data (e.g. see the review by Terza et al. [79]).
7  Adjusting for Baseline Covariates: 
Conceptual and Statistical Considerations
Randomisation is a common method used within trials to 
control for systematic bias between groups often associated 
with selection and confounding biases; however, this method 
will not always result in perfect balance between groups and 
therefore statistical methods can be used, such as adjust-
ing for covariates. Although almost two decades old, there 
is guidance on statistical principles for clinical trials that 
briely addresses the problem of adjustment for covariates 
to control for systematic bias and which is still relevant [80]. 
Key aspects to note from this guidance when adjusting for 
covariates are:
1. Identify covariates expected to have an important inlu-
ence on the outcome of interest.
2. Account for these covariates in the analysis in order to 
improve precision and to compensate for any lack of 
balance between groups.
3. Apply caution when adjusting for covariates measured 
after randomisation because they may be afected by the 
treatments.
It should be noted that adjusting for baseline covariates is 
not always necessary or recommended [81], and the starting 
point for any within-trial CEA should be unadjusted analy-
ses; however, in the case of a strong or moderate association 
between baseline covariate(s) and the outcome of interest, 
adjustment for such covariate(s) generally improves the ei-
ciency of the analysis and the results should be reported 
alongside the unadjusted analyses. A pragmatic approach 
may also be preferred whereby the logistical, time, and 
resource constraints to collect baseline data may not be 
possible within a study, particularly if obtaining this data 
from study participants can overburden the participant (e.g. 
in terms of time or cognitive burden). As such, researchers 
should consider the need for baseline adjustment and make 
appropriate hypotheses rationalising the need for baseline 
data at the start of the study. There are a number of methods 
for adjusting for baseline covariates, but regression model-
ling using baseline covariates as explanatory variables is 
recommended [81]. There are many types of baseline covari-
ates and their nature depends on the context of the study 
and the analysis. When analysing trials, the main statistical 
analysis (i.e. focussed on the trial’s primary outcome) will 
predeine a set of covariates for which to control, and these 
are a useful starting point for the choice of covariates for the 
analysis of costs.
In relation to CUA, Manca et al. [82] have discussed the 
importance of controlling for baseline utilities when the out-
come of interest is the (utility-based) QALY. While the focus 
here is on costs, this does not negate the need to control for 
other baseline covariates associated with the ‘efectiveness’ 
(i.e. QALY or otherwise) aspect of CEA. van Asselt et al. 
[83] has discussed how to control for baseline cost difer-
ences for CEA. They recommend the use of a regression-
based adjustment using baseline patient characteristics or, 
when these are not suiciently present, baseline costs as 
a substitute. Franklin et al. [48] have made the case that 
adjusting for baseline costs is important in their own right, 
not just as a substitute to patient characteristics. They also 
suggest that there may be bias related to the data record-
ing mechanisms (routinely collected primary care data in 
this case study) and ‘frequent attenders’ (those who utilise 
services more than the ‘norm’), which can be controlled 
for using a regression-based baseline adjustment. However, 
before controlling for costs at baseline, there is also the need 
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to (1) assess the relationship between your baseline covari-
ates, including costs, to avoid collinearity; and (2) consider 
which covariates to include as hypothesised to be relevant 
a priori (i.e. per-protocol analysis). In relation to the second 
point, this does not necessarily restrict the ability to also 
conduct exploratory, post hoc adjustments with diferent 
covariates to assess if there is a relationship (i.e. strength 
and statistical signiicance) between baseline variables and 
the outcomes of interest that could inform future analy-
ses plans. Accounting for various forms of heterogeneity 
in CEA has been discussed by Sculpher [10] in relation to 
performing subgroup analysis, although many of the points 
raised are also relevant when deciding on what covariates to 
include for the purpose of baseline adjustments and general 
statistical analysis between groups and subgroups (see also 
Sect. 6).
8  Dealing with Diferent Types of Missing 
and Censored Cost Data
Missing data can be a source of bias and uncertainty, and 
is a common occurrence with patient-level data. Within 
trials, this can occur due to factors such as poor reporting 
rates, incomplete reporting of data, and patients being lost 
to follow-up (e.g. study dropout; inability to complete a 
study). Even when using routine datasets, missing data can 
be problematic for reasons such as ‘censoring’ (i.e. the data 
are not collected or are not used for analysis). Issues with 
missing data may be a study design law that requires better/
further/repeat data collection (see also Sect. 5); however, for 
the purpose of this section, the focus will be on how to deal 
with missing data using statistical methods. First, it is up 
to the analyst to determine the ‘types of missingness’. For 
example, are the data:
1. Missing completely at random (MCAR): no relationship 
between the data that are missing and for any values in 
the dataset, missing or observed.
2. Missing at random (MAR): no relationship between the 
missing data and mechanism for missingness, but this 
mechanism may be related to the observed data.
3. Missing not at random (MNAR): there is a relationship 
between the missing data and the mechanism for miss-
ingness.
Dealing with missing data has been explored and 
described in more detail by Little and Rubin [84]. Note that 
if the data are MCAR, then little needs to be done statis-
tically at this point as MCAR does not imply systematic 
bias in your data; however, MCAR may be important if 
it reduces the statistical power of the analysis. Complete 
case analysis (CCA; i.e. using only those patients with no 
missingdata) is valid if complete cases are representative 
of the whole sample; if CCA is used, then an appropriate 
rationalisation/assumption should be provided as to why the 
complete cases are representative of the whole sample in the 
context of the intended analysis [85]. Like CCA, there are 
a number of other commonly used methods that have been 
applied to allow for missing data, a summary of which have 
been described by Briggs et al. [86] and include available 
case analysis, mean imputation, regression imputation, last 
value carried forward, and hot decking, each of which have 
their issues, e.g. mean imputation and regression imputa-
tion tend to not capture variability and can underestimate 
standard errors. However, despite some limitations, when 
data are determined to be MAR or MNAR, imputation is still 
commonly used to predict missing data. There are multiple 
univariate or multivariate methods for imputation, which can 
include using linear and logistic regressions of various types 
[87], predictive mean matching [88], and multiple imputa-
tion (MI) using chained equations (MICE) [89]. MICE has 
become particularly popular over the last decade and guid-
ance on using this method has been described by White et al. 
[89]. Although MI is generally regarded as being more ei-
cient, inverse probability weighting (IPW) may sometimes 
be preferred if incomplete cases provide little information 
[90]. The IPW approach corrects for the selection bias in 
the observed cases by weighting the complete cases with 
the inverse of their selection probabilities (i.e. IPW models 
the selection probability, such that it is a model for the prob-
ability that an individual is a complete case), whereas MI 
models the data distribution (i.e. a model for the distribu-
tion of the missing values given the observed data), which 
can be biased by the data distribution of the observed data, 
and which is problematic if the observed data suggest little 
about the unobserved data. As such, there has been a recom-
mendation to combine the two approaches to improve the 
robustness of estimation in the literature, the practicalities 
around which have been discussed elsewhere [90, 91]. It 
is also recommended that sensitivity analyses to assess the 
robustness of the study’s results to potential MNAR mech-
anisms should be conducted [85]. Heckman models have 
also been suggested to extend the validity of MI to some 
MNAR mechanisms, although as the current authors are not 
aware of the extent to which Heckman models have been 
applied speciically for CEA, references are provided here 
mainly for the interested reader [92, 93]. It has been noted 
that for HTAs, the CCA or MI methods appear to be the 
most commonly used for CEA, relative to IPW and includ-
ing sensitivity analyses [85], the suggestion being a need 
for improvement when dealing with missing data for CEA 
as, in many cases, CCA is not appropriately rationalised but 
is still used without considering and rationalising the most 
appropriate methods for dealing with, or assessing the efect 
of, missing data.
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Censored data can be considered a special case of missing 
data. A key assumption when applying conventional survival 
analysis methods to censored cost data is that the uncensored 
data are the same as the censored data (i.e. the censored 
data are ‘uninformative’). However, future resource use and 
associated costs can be dependent on past resource use and 
associated costs, and therefore the censored data may be 
informative. Thus, the assumption that censored data may 
be uninformative is not valid and therefore censored data 
can lead to bias within CEA. Methods exist allowing for 
censoring that overcomes this assumption, using a weighting 
of costs with or without covariate adjustments. Adjusting 
for baseline cost diferences may result in being able to deal 
with censoring if it is constant across the baseline and fol-
low-up time periods of interest, but, again, this is an assump-
tion (see also Sect. 7). Dealing with censored data has been 
discussed by Young [94], Drummond and McGuire [95], 
Willan et al. [96], and Wijeysundera et al. [97]. The inter-
ested reader may also wish to explore the related literature 
regarding the handling of censoring in survival analysis [98].
9  Uncertainty Around Cost Estimates
All economic evaluations are subject to uncertainty, whereby 
we consider uncertainty to refer to the fact that the expected 
costs and efects of a treatment are not known with certainty, 
as opposed to variability (i.e. random diferences in costs 
and efects between identical individuals) and heterogene-
ity (i.e. variability in costs and efects between individuals 
that can be attributed to their characteristics) [99, 100]. The 
importance for economic evaluations of properly character-
ising uncertainty, estimating its consequences, and appropri-
ate policy actions to address this uncertainty (i.e. research 
and adoption decisions) have been widely discussed in the 
literature [101–105]. In this section, we briely discuss the 
methods for characterising this uncertainty with regard to 
costs.
Uncertainty in economic evaluations is normally dealt 
with in two ways: deterministic sensitivity analysis, whereby 
single or groups of parameters are varied to assess the 
impact on results, or probabilistic sensitivity analysis (PSA), 
which assesses the joint uncertainty (based on the uncer-
tainty across all inputs) [102]. Only the latter of these allows 
for the full characterisation of uncertainty.
When conducting deterministic sensitivity analysis 
around costs, unit costs and resource-use estimates may be 
varied to examine the impact on results, with the ranges 
chosen often being arbitrary. For PSA, distributions must 
be assigned to indicate the uncertainty. If the parameter 
relates to a unit cost that is considered ixed, it may not be 
appropriate to consider any uncertainty. In contrast, costs are 
likely to be subject to uncertainty and distributions should 
be assigned.
As discussed in Sect. 3, there are two main vehicles for 
economic evaluation—trial-based and model-based. The 
approaches to characterising uncertainty in costs using PSA 
difers between these two vehicles, although there are some 
common themes.
For trial-based evaluations, typically the total or incre-
mental costs between arms are estimated using econometric 
analysis. The uncertainty in this estimate can be estimated 
non-parametrically using techniques such as bootstrapping 
[106], or parametrically by itting a distribution to the model 
(e.g. multivariate normality) [8] to see how the joint uncer-
tainty in explanatory variables in the econometric model 
impact the outcome. Both types of approach allow the char-
acterisation of uncertainty around the cost estimate (e.g. via 
conidence intervals) and its subsequent impact on decision 
uncertainty, i.e. the probability that a given intervention is 
cost efective, often diagrammatically presented as part of a 
cost-efectiveness acceptability curve (CEAC) [20].
For model-based evaluations, probabilistic distributions 
are placed on uncertain parameters and then the uncertainty 
through the whole model is propagated using Monte Carlo 
simulation to estimate the impact on costs and efects. While 
the uncertainty in all parameters may drive the uncertainty 
in total costs, we focus on appropriate distributions for cost 
variables (which could include resource use and associ-
ated unit costs). As has been previously discussed, costs 
(and resource use) are bound at zero and are typically right 
skewed. As such, probabilistic distributions such as the 
Gamma distribution are appropriate for characterising the 
uncertainty in mean cost parameters [8].
A further underconsidered issue in uncertainty around 
costs is how costs may change over time. Claxton et al. [103] 
have shown how cost changes over time can alter the value 
of interventions and change the appropriate policy decision.
10  A Note on Discounting, Inlation, 
and Using Relevant Currency
For CEA, both costs and efects need to be adjusted for 
the diferent times that they occur, although discounting is 
generally only applied when the time horizon of interest is 
> 12 months. Discounting is a mathematical procedure to 
adjust future costs to their present value, efectively reducing 
them by a speciied proportion based on the discount rate 
and how far they are in the future.
Discounting has been rationalised to account for factors 
such as time preferences in the receipt of costs or efects, 
such that we value future events lower than current events,as 
well as the rate of return on capital and change in produc-
tivity over time [107]. NICE uses a rate of 3.5% for both 
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costs and beneits, although 1.5% can be used for sensitiv-
ity analyses [2, 108]. Discounting can be performed using 
group means or individual-level data, although the latter is 
preferred, particularly due to issues associated with missing 
data (see also Sect. 8). Recently, Attema et al. [109] have 
reviewed the issues and debates around discounting, describ-
ing and discussing the current discounting recommendations 
of countries publishing their national guidelines. Other use-
ful references include the work of Claxton et al. [107] and 
Tinghög [110].
In some cases, there may be the need to inlate diferent 
unit costs so that all unit costs relect a common cost year, 
which is typically the most recent year at the time of analysis 
and/or the most recent year for available unit costs (where 
inlation refers to mathematically scaling up a cost to relect 
a general increase in prices). There are various inlation 
indices that can be used depending on the type of resource 
associated with the unit cost. For example, the PSSRU Unit 
Costs of Health and Social Care [57] has a list of inlation 
indices for the UK that includes the Hospital and Commu-
nity Health Services (HCHS) index, Personal Social Ser-
vices (PSS) pay and prices index, Gross Domestic Product 
(GDP) delator and the tender price index for public sector 
buildings, and the Building Cost Information Service (BCIS) 
house rebuilding cost index and the retail price index.
It is common practice to represent cost in the currency of 
interest to the decision maker. For example, if the remit of 
the study is England and the evidence is being generated for 
NICE, then Great British pounds sterling (GBP; £) would be 
the common currency. However, in the case of multinational 
trials and/or if there are multiple decision makers from dif-
ferent countries for whom the evidence is being generated, 
there may be the need to apply an exchange rate (i.e. a rate 
representing the value of one currency relative to another) 
to costs (be it unit costs or overall costs). For multinational 
trials, how costs are dealt with is dependent on if a pooled 
(i.e. combine all cost and efects across countries), split (i.e. 
produce cost and efect results only in their country-speciic 
setting) or partial/combined (e.g. pool only data from coun-
tries with comparable healthcare systems or using a common 
currency such as the Euro (€), with all other country results 
analysed for their own setting only) approach is taken. There 
is no clear consensus on how best to conduct economic eval-
uations in the context of multinational trials. The methods 
used for conducting an economic evaluation in the context of 
a multinational trial have been considered by three diferent 
literature reviews by Reinhold et al. [111] and Oppong et al. 
[112], with Vemer and Rutten-van Mölken [113] focussing 
speciically on statistical methods used to enable transfer-
ability between country settings. Manca et al. [114] have 
critically appraised the methodologies used for CEA as part 
of multinational trials, and a general discussion about the 
transportability of comparative cost efectiveness between 
countries has been discussed by Briggs [115], with ‘good 
practice’ guidance suggested by Drummond et al. [116].
11  Recommendations for Future Analyses 
and Research
Although checklists exist for use alongside CEA (e.g. 
CHEERS), there is still poor reporting and rationalisa-
tion of statistical methods and covariate adjustments when 
using cost data. This aspect does not necessarily need to 
be part of a new checklist as it can be amalgamated into 
existing checklists to avoid overburdening researchers with 
more checklists. What is more important is that research-
ers give careful consideration as to why they have cho-
sen a speciic regression model and associated covariates 
rather than using whatever is observed in a similar study 
in the empirical literature, e.g. if another study has used 
OLS adjusting for baseline costs, this does not necessarily 
mean doing exactly the same is appropriate in a similar 
study. Researchers should critically assess what covariates 
to include (e.g. age, gender), and it is up to researchers 
to suggest and appropriately rationalise what covariates 
are or are not important, as hypothesised a priori. Such 
hypotheses should be based on clinical and empirical 
knowledge, relecting on (but not simply repeating) exist-
ing studies and analyses in the empirical literature. It is 
also important to consider what adjustments can be con-
ducted post hoc, which could form exploratory analysis (as 
opposed to per-protocol) to inform developing hypotheses 
within future studies.
From the current authors’ perspectives, there is a lack 
of papers where baseline adjustments have been made 
or appropriately rationalised for the purpose of CEA. 
Although there is no up-to-date systematic review to sup-
port this claim related to costs, a review by Richardson and 
Manca [117] published in 2004 noted that most published 
trial-based CUA studies failed to recognise the need to 
adjust for imbalance in baseline utility. The current authors 
feel a lack of more generalised (i.e. not just adjusting for 
baseline utility) and rationalised baseline adjustments for 
CEA is still apparent; however, we recognise the need to 
conduct a systematic review to fully support this claim.
The external validity of RCTs has been raised in the 
literature with regard to, for example, patient selection and 
use of exclusion criteria. One particular issue with trials 
for informing costs is the presence of protocol-speciic 
resource use that would not be expected in usual practice 
(e.g. additional physician appointments for data collec-
tion). When such costs are present, it may be sensible to 
include additional analyses in instances where they are 
excluded. This is an addition to other methods that can be 
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used to adjust trial analyses to make them more representa-
tive of the target population in real-world use [118].
With the increasing use of observational data in CEA, 
future research should consider the use of statistical and 
econometric methods that can control for unobserved con-
founding. This is the case not only for the treatment efect 
on costs but also the estimation of event or health state 
costs for the purposes of modelling. When analysing trials 
for the purposes of informing decision model parameters 
such as these, methods to control for unobserved con-
founding may still be useful since randomisation can be 
broken at the point of a clinical event or reaching a speciic 
health state.
In this paper, we have taken it as given that unit costs rep-
resent the true monetary value of a resource. However, unit 
costs may not represent the true value of a resource, with 
resources potentially being more constrained than others, 
and unit costs not adjusting immediately such that marginal 
productivity is equalised across healthcare resources. This 
raises issues for the aggregation of costs across diferent 
types of resource use to estimate a total healthcare cost [119, 
120]. Consideration may be given to the estimation of cost 
categories for more disaggregated resource use in such situ-
ations. In addition, while the focus of this paper has been 
cost analysis, for CEA it is the joint distribution of costs and 
efects which determine cost efectiveness. More research 
needs to consider the appropriate bivariate modelling of 
such data, given the underlying statistical properties of the 
two types of data.
12  Conclusion
There has been a tendency to overlook the complicated 
nature of cost data and how to include it in CEA, the con-
sequence of which is that inconsistent estimates could be 
produced across studies that do not appropriately control 
for the nature of cost data and the uncertainty around 
subsequent cost estimates. This could lead to inaccurate 
information being given to decision makers. This paper 
has outlined important considerations when using cost 
data for CEA, while noting that further research needs to 
be conducted in this area. Researchers need to carefully 
consider how to account for costs within their speciic eco-
nomic evaluation.
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